navigation navigation
navigation

News

26 Jul 2021

toggle

Trilantic Europe invests in Smile Eyes Group

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

19 Jul 2021

toggle

Repsol and Talgo to jointly develop a renewable hydrogen-powered train

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

23 Jun 2020

toggle

Trilantic Europe supports add-on acquisitions to bolster its healthcare portfolio in Italy and Germany

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

9 Apr 2020

toggle

Trilantic Europe portfolio companies are actively providing resources and know-how as well as making in-kind philanthropic contributions to support health authorities in their fight against COVID-19

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

23 Oct 2019

toggle

Trilantic Europe fully exits its successful investment in Gamenet

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

4 Sep 2019

toggle

Trilantic Europe supports two bolt-on acquisitions for Oberberg

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

30 Jul 2019

toggle

Trilantic Europe partially monetises its investment in Gamenet

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

21 Nov 2018

toggle

Talgo awarded 2018 Internationalization Award

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

28 Sep 2018

toggle

YM&U joins forces with Trilantic Europe following rebrand

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

24 Jul 2018

toggle

Gamenet Group signed the agreement for the acquisition of 100% of GoldBet

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

15 Dec 2017

toggle

Trilantic Europe invests in the Oberberg Group

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

6 Dec 2017

toggle

Gamenet Group completed the listing on Borsa Italiana

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

4 Dec 2017

toggle

Elisabetta Franchi purchases 25% of Betty Blue S.p.A. from Trilantic Europe

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

2 Nov 2017

toggle

Talgo shortlisted for HS2 rolling stock procurement

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

1 Jun 2017

toggle

Trilantic Europe invests in leading bioethanol business in Spain and France

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

7 Apr 2017

toggle

Trilantic Europe becomes a shareholder in Pacha Group

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

28 Nov 2016

toggle

Talgo wins the most important high-speed tender in Europe with its new Avril, the most advanced high-speed train

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

24 Feb 2016

toggle

Trilantic Europe Invests In Maugeri, Leading Italian Non-Acute Private Hospital Operator

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

13 Oct 2015

toggle

Trilantic Europe completes acquisition of 90% stake in leading Italian pharmaceuticals producer Doppel Farmaceutici

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

1 Jul 2015

toggle

Trilantic Europe raises €900 million

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

1 Jul 2015

toggle

IPO of Trilantic Europe IV’s portfolio companies, Talgo and Euskaltel

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

26 Mar 2015

toggle

Prettl and Trilantic Europe announce a partnership agreement

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

14 Jan 2015

toggle

Trilantic Capital Partners has realised its investment in Clarion Events

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

17 Oct 2013

toggle

Trilantic acquires stake in Elisabetta Franchi

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

16 Sep 2013

toggle

Gamenet successfully issues €200mn in its debut bond offering

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

26 Jun 2013

toggle

Spain's Talgo Awarded €482 million Contract In Kazakhstan

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

20 Nov 2012

toggle

Trilantic Europe exits Istanbul Doors Group, owner of the leading restaurants in Istanbul and Tom Aiken’s restaurants in London

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

14 May 2012

toggle

Marex Spectron to acquire Schneider Trading Associates Pro-Trader Division

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

12 Dec 2011

toggle

Talgo manufacturing facility opens in Kazakhstan

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

26 Oct 2011

toggle

Talgo awarded the High-Speed Mecca-Medina mega-contract

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

12 Apr 2011

toggle

Michel Léonard joins Trilantic Capital Partners as operating partner

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

24 Mar 2011

toggle

The Istanbul Doors Restaurant Group Acquires the Restaurant Business of Michelin-Starred Chef Tom Aikens

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

22 Mar 2011

toggle

Marex Group Reaches Agreement to Acquire Spectron Group

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

14 Feb 2011

toggle

Appointment of John Danilovich to Trilantic European Advisory Council

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

17 Jan 2011

toggle

Refresco Group Announces its Intention to Acquire Spumador

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

14 Jan 2011

toggle

Trilantic Capital Partners commits up to €50 million in LeYa

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

7 Jan 2011

toggle

Trilantic Capital Partners to Invest €53 million in Gamenet

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

11 Nov 2010

toggle

Talgo is awarded the contract to renew and expand the intercity passenger train coaches of the national railway company of Kazakhstan

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

28 Jul 2010

toggle

Thai Union Frozen Products Board of Directors Approves Acquisition of MW Brands from Trilantic Capital Partners

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

10 Feb 2010

toggle

Trilantic Capital Partners has Successfully Realized its Ownership Stake in Industria de Turbo Propulsores S.A.

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

24 Sep 2009

toggle

Talgo: Spanish Minister of Transportation to Support Talgo in its Internationalization

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

17 Jul 2009

toggle

Talgo: Governor Doyle Announces Agreement with Talgo to Bring New Trains, Assembly and Maintenance Facilities to Wisconsin

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

9 Apr 2009

toggle

Istanbul Doors: Group Launches New Italian Restaurant Concepts

Trilantic Europe, the private equity firm focused on mid-market transactions in Europe, today announces its investment in the Smile Eyes Group, a leading player in the German ophthalmology market headquartered in Munich. The investment is structured as a partnership between Trilantic Europe, the two co-founders of Smile Eyes Dres. Wiltfang and Bechmann and the management team, with the vision to implement a buy-and-build strategy in the German ophthalmology market. The financial details of this transaction are not disclosed.

Smile Eyes is a leading and highly specialised healthcare operator with a comprehensive service offering in the field of ophthalmology in various metropolitan regions in Germany. Smile Eyes stands for eye laser and lens surgery at the highest medical level and is at the forefront of innovation and research to provide its patients with the best available treatment options. In addition to its expertise in laser treatments and lens surgery, the group offers treatment of eye diseases such as cataracts, retinal diseases, or glaucoma as well as aesthetic corrections.

Henrik Bodenstab, Partner at Trilantic Europe, said: “We are impressed by Smile Eyes’s attractive position in the German ophthalmology market. Dres. Wiltfang and Bechmann have built an impressive network of highly specialised ophthalmic experts and we are excited to partner with them and their team to support their expansion strategy centred around the Smile Eyes concept.”

Dr. med. Rainer Wiltfang and Dr. med. Martin Bechmann, Founders and Managing Directors of Smile Eyes, added: “We are delighted to announce our partnership with Trilantic Europe and are looking forward to working hand-in-hand with the Trilantic Europe team to implement our growth strategy for Smile Eyes.”

The transaction represents Trilantic Europe’s sixth investment in the European healthcare sector and the first investment for Trilantic Europe VI.

Press Enquiries

For further information and enquiries, please contact:

Agnès Riousse, Citigate Dewe Rogerson: agnes.riousse@citigatedewerogerson.com

Nick Reading, Citigate Dewe Rogerson: nick.reading@citigatedewerogerson.com

About Trilantic Europe

Trilantic Europe is a pan-European private equity firm with c.€2bn under management focusing on mid-market transactions, tailoring solutions for businesses using its expertise and operating knowledge to accelerate growth and enhance value creation. Trilantic Europe’s sectors of focus are healthcare, consumer & leisure, industrials, TMT and business services. For further information, please refer to https://www.trilanticeurope.com/

About Smile Eyes

Smile Eyes is a leading player in the German ophthalmology market with headquarters in Munich. For further information, please refer to https://www.smileeyes.de/

Contact

Trilantic Europe

London

35 Portman Square
London, W1H 6LR
United Kingdom

Guernsey

Trafalgar Court
St Peter Port
Guernsey, GY1 4LY

Luxembourg

26 Bd Royal
L-2449 Luxembourg
Luxembourg